In lymphocytes, the phosphoinositide 3'-kinase (PI3K) isoform p110δ (PI3Kδ)
Introduction
Chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, is characterized by the accumulation of CD5 + /CD23 + monoclonal B cells in the blood and tissue compartments (marrow and secondary lymphatic tissues) 1 . CLL cells are resistant to cell death in vivo.
However, they rapidly die from spontaneous apoptosis once removed from the patient unless they are co-cultured with accessory stromal cells, such as marrow stromal cells (MSCs) 2 or monocyte-derived nurse-like cells (NLCs) The chemokines, CXCL12 and CXCL13, are constitutively secreted by MSCs and NLCs 5, 6 and attract CLL cells via their respective cognate chemokine receptors, CXCR4, CXCR5, thereby regulating homing and retention of the leukemia cells in the tissue compartments. In addition, BCR signaling in the lymphatic tissue microenvironment promotes the clonal expansion of normal and malignant B cells 1, 7, 8 . CLL cells isolated from lymph nodes 8 or high-risk patients 9 display gene expression profiles that indicate BCR activation. In response to BCR activation and in NLC co-cultures, CLL cells secrete the chemokines CCL3 and CCL4 (also called MIP-1α and β ) 10 , presumably for recruitment of accessory cells, such as regulatory T cells 11, 12 . We proposed that the secretion of CCL3 and CCL4 by CLL cells correlates with the responsiveness can develop inflammatory bowel disease [16] [17] [18] .
CAL-101 is a potent and highly selective PI3Kδ inhibitor 19 that promotes apoptosis in B-cell lines and primary cells from patients with different B-cell malignancies, including CLL 20 , mantle cell lymphoma and multiple myeloma 19, 21 .
CAL-101 inhibits constitutive and CD40-, TNF-alpha-, fibronectin-, and BCRderived PI3K signaling leading to suppression of Akt activation 19, 20, 21 . These studies suggested that disruption of intrinsic and extrinsic survival signals could be a critical mechanism for the clinical activity of CAL-101.
In CLL patients, CAL-101 induces a re-distribution of CLL cells from the tissue compartments into the blood, causing a rapid and sustained lymph node size reduction and a transient lymphocytosis during the first weeks of treatment purchased from the Riken cell bank (Tsukuba, Japan) and maintained in RPMI 1640 medium supplemented with 2.05-mM L-glutamine (HyClone, Logan, UT), 10% FBS (SAFC Biosciences), and penicillin-streptomycin (Cellgro, Manassas, VA). The murine stromal cell line TSt-4 derived from fetal thymus tissue (also from Riken) was maintained in RPMI 1640 medium supplemented with 2.05-mM L-glutamine, 5% FBS, and penicillin-streptomycin. CLL cell viability was determined by analysis of mitochondrial transmembrane potential using 3,3' dihexyloxacarbocyanine iodide (DiOC 6 ; Molecular Probes, Invitrogen, Carlsbad, CA) and by cell membrane permeability to propidium iodide (PI) (Sigma) 23 . CAL-101 was provided by Calistoga Pharmaceuticals (Seattle, WA) and was dissolved in dimethyl sulphoxide (DMSO) at 10 mM and stored at -20°C until use.
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Chemotaxis assay
To determine the effect of CAL-101 on CLL cell chemotaxis, we performed chemotaxis assays across polycarbonate Transwell inserts as described 5 . Briefly, CLL cells (10 7 /mL) were incubated at 37°C in 5% CO 2 with 10 μg/mL of anti-IgM (MP Biomedicals, Solon, OH) in complete RPMI medium with or without 5 μM CAL-101. After 1 hour, CLL cells were centrifuged and re-suspended in RPMI 1640 with 0.5% bovine serum albumin to a concentration of 10 7 cells/mL. 100 μL of cell suspension was added to the top chamber of a Transwell culture insert (Corning, Corning, NY) with a diameter of 6.5 mm and a pore size of 5 μm. Filters then were transferred to wells containing medium with or without 200 ng/mL of CXCL12 (Upstate Biotechnology, Charlottesville, VA) or 1 μg/mL of CXCL13
(R&D Systems, Minneapolis, MN). The chambers were incubated for 3 hours at 37°C in 5% CO 2 . After this incubation, the cells in the lower chamber were suspended and divided into aliquots for counting with a FACSCalibur (BD Biosciences, Franklin Lakes, NJ) for 20 seconds at 60 μL/min in duplicates.
A 1/20 dilution of input cells was counted under the same conditions.
Migration assay evaluating CLL pseudoemperipolesis
Pseudoemperipolesis is an in vitro phenomenon in which CLL cells spontaneously migrate beneath marrow stromal cells in a CXCR4-dependent fashion; the effect mimics in vivo migration and homing to stromal cells in the tissues 5, 24, 25 . We quantified CLL cell pseudoemperipolesis, as described 5 . Briefly, the murine stromal cells (R-15C and TSt-4) were seeded the day before the assay onto collagen-coated 12-well plates at a concentration of 
Multiplex assay (human cytokine assay)
NLC co-cultures provide a mode of stimulation to CLL cells that is strikingly similar to that observed in lymph nodes 8, 10 , and therefore represent the best in vitro model to study the lymph node microenvironment. To better 
Data analysis and statistics
Results are shown as mean plus or minus standard error of mean (SEM) of at least 3 experiments each. For viability assays, mean relative viabilities were determined to account for variability in spontaneous apoptosis rates in different patient samples. The mean relative viability was defined as the mean CLL cell viability of a particular sample (treated with drug in the presence or absence of MSC at a given time point), divided by the mean cell viability of the same sample at the same time point of control CLL cells, cultured in suspension culture. As appropriate for the analysis, Student's paired or unpaired t-tests were used for statistical comparisons. Analyses were performed using GraphPad Prism 4 software for Macintosh (GraphPad Software, San Diego, CA). A P-value less than 0.05 was considered as statistically significant. Flow cytometry data were analyzed using the FlowJo software (TreeStar, Ashland, OR).
Results

CAL-101 inhibits CLL cell chemotaxis and migration beneath marrow stroma cells (pseudoemperipolesis)
In (Figure 3B ). Subset analyses again did not show significant differences between IGHV mutated or unmutated CLL cases (supplemental Fig. S3 ).
CAL-101 inhibits NLC-and BCR-induced secretion of the chemokines, CCL3, CCL4, and CXCL13
As illustrated in Figure 4A , activation of CLL cells via the BCR using anti-IgM resulted in marked increases in secretion of CCL3 and CCL4. In samples from 5 patients, this effect was significantly inhibited by CAL-101 in a dose-dependent manner.
As shown in Figure 4B -D, co-culture with NLCs also induced the CLL cells to secrete high concentrations of CCL3 and CCL4 into the supernatants. Figure   4B showes the results from 5 patients, the respective mean (±SEM) CCL3 and CCL4 concentrations in supernatants of untreated CLL cells after NLC co-culture for 24 hours were 943.3 (±535.9) pg/mL and 7433.3 (±4463.1) pg/mL, which are comparable to our previously experience 
CAL-101 sensitizes CLL cells to cytotoxic drugs in MSC co-cultures
Previous studies have demonstrated that MSC can protect CLL cells from drug-induced apoptosis 23, 25, 26 . Therefore, we evaluated whether CAL-101 could enhance CLL cell killing when these cells were co-cultured with MSC in the presence of drugs that are cytotoxic to CLL cells (bendamustine, fludarabine, and dexamethasone). Figure 6A Figure S4 ). . These data, along with the early notion of proliferation centers (also called pseudofollicles) 31 , and the subsequent characterization of proliferation centers as sites of CLL cell proliferation and engagement with accessory (T) cells 11, 12 , point towards the secondary lymphatic tissues as the principal site for hosting BCR-and T-cell-driven CLL cell proliferation, accounting for a turnover of 0.1% to greater than 1.0% of the CLL clone per day 
CAL-101 inhibits BCR-, CXCL12-, and CXCL13-induced AKT-and ERKactivation in CLL cells
